Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Dramatic Survival Benefit with Nivolumab in Melanoma

DOI: 10.1158/2159-8290.CD-NB2016-044 Published June 2016
  • Article
  • Info & Metrics
Loading

More than a third of patients with metastatic melanoma who were treated with the immunotherapeutic nivolumab (Opdivo; Bristol-Myers Squibb) are still alive after 5 years, researchers reported April 17 at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, LA. The latest follow-up data from a phase I trial launched in 2008 indicate that nivolumab's benefits can persist long after treatment ends.

“These data provide a foundation for establishing anti–PD-1 therapy as another standard for melanoma patients, and hopefully this would translate to other cancer types as well,” said the trial's principal investigator, F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute in Boston, MA.

The FDA approved nivolumab for melanoma in 2014, and for lung cancer and renal cell carcinoma in 2015. An immune checkpoint inhibitor, the monoclonal antibody blocks PD-1, boosting the body's antitumor response.

The phase I study enrolled 107 patients with advanced melanoma who had received at least two previous therapies. Each patient received the drug for up to 96 weeks; some stopped treatment sooner due to adverse effects or because their tumors were completely eradicated. In early results, published in the Journal of Clinical Oncology in 2014, tumors shrank in 31% of the participants, and their estimated median duration of response was 2 years.

According to the new data, 34% of patients were still alive after 5 years. Overall survival began to plateau around 4 years, indicating that those who lived that long would likely continue to experience a durable response. Although the study had no control group, this survival rate is well above what was typical for patients with metastatic melanoma around the time of the study's start. According to the NCI's Surveillance, Epidemiology, and End Results Program, 5-year survival between 2005 and 2011 averaged 16.6%.

Hodi also reported on five patients who initially responded to the drug but suffered a recurrence after being off of it for at least 100 days. Each restarted treatment with nivolumab at their original dose, and all responded for at least 6 months, with one still experiencing a complete response nearly 2 years later.

What makes nivolumab and other immunotherapeutics so exciting is the durability of response, said Louis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, who moderated the press conference at which Hodi presented his results. Although chemotherapies and targeted therapies can control cancer, drug resistance is common and can emerge within weeks or months.

Several questions remain. For example, scientists are not certain whether using nivolumab in combination with the CTLA-4 inhibitor ipilimumab (Yervoy; Bristol-Myers Squibb), will further prolong survival. Data supporting this one–two punch aren't yet available, but Hodi predicted that pairing the drugs might lead to better survival rates than either alone.

It's also uncertain how nivolumab compares to another anti–PD-1 immunotherapeutic, pembrolizumab (Keytruda; Merck), for the treatment of melanoma, because the two have not been studied head to head, Hodi noted. –Amber Dance

  • ©2016 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 6 (6)
June 2016
Volume 6, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dramatic Survival Benefit with Nivolumab in Melanoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dramatic Survival Benefit with Nivolumab in Melanoma
Cancer Discov June 1 2016 (6) (6) OF7; DOI: 10.1158/2159-8290.CD-NB2016-044

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dramatic Survival Benefit with Nivolumab in Melanoma
Cancer Discov June 1 2016 (6) (6) OF7; DOI: 10.1158/2159-8290.CD-NB2016-044
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Congress Approves Increase in Cancer Funding
  • Tasmanian Devil Facial Tumor Disease Turns Endemic
  • Proteomics Sharpens Brain Tumor Genomic Analysis
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement